16 completed, 4 terminated, 2 unknown, 1 active not recruiting. 26 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 26 | Completed 16, Terminated 4, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 4, Withdrawn 1 |
Follow Chronic Myeloid Leukemia: new trials by email Literature Review of Chronic Myeloid Leukemia trials Research Report on Chronic Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 408 | 2026-12-01 | 2026-10-21 |
| Study of Olverembatinib (HQP1351) in Patients With CML-CP olverembatinib, Bosutinib - Chronic Myeloid Leukemia, CML | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 333 | 2024-02-05 | 2026-09-15 |
| Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System treatment of TKI in CML - Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia | Phase 3 | Active not recruiting | Poitiers University Hospital | 170 | 2023-12-01 | 2026-04-27 |
| Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML Asciminib, Imatinib - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive | Phase 3 | Terminated | Sarit Assouline | 8 | 2023-11-01 | 2026-05-29 |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia | Phase 3 | Completed | Dartmouth-Hitchcock Medical Center | 21 | 2018-03-28 | 2026-07-17 |
| Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients Nilotinib (Tasigna ®), capsules of 150 mg, Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®) - Chronic Myeloid Leukemia | Phase 3 | Completed | Hospices Civils de Lyon | 200 | 2014-08-01 | 2025-10-02 |
| An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years Imatinib, Nilotinib - Chronic Myeloid Leukemia | Phase 3 | Terminated | Prof. Dr. Nikolas von Bubnoff | 14 | 2014-03-01 | 2019-12-02 |
| Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions Imatinib Mesylate Tablets, 400 mg - Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumor | Phase 2 / Phase 3 | Completed | Amneal Pharmaceuticals, LLC | 48 | 2014-02-01 | 2014-06-27 |
| Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis ARM A Cyclophosphamide, ARM B Calcineurin inhibitor and methotrexate - Acute Myelogenous Leukemia, Acute Lymphoid Leukemia | Phase 3 | Terminated | Hospital Israelita Albert Einstein | 3 | 2012-12-01 | 2017-03-03 |
| TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study Peginterferon α2b, Nilotinib - Chronic Myeloid Leukemia | Phase 3 | Completed | University of Jena | 717 | 2012-08-24 | 2023-05-10 |
| Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) ponatinib, imatinib (Gleevec/ Glivec) - Chronic Myeloid Leukemia | Phase 3 | Terminated | Ariad Pharmaceuticals | 307 | 2012-06-01 | 2014-11-17 |
| European Stop Tyrosine Kinase Inhibitor Study Stopping treatment with TKI - Chronic Myeloid Leukemia | Phase 3 | Completed | European LeukemiaNet | 868 | 2012-05-30 | 2021-11-05 |
| Nilotinib in PH+, BCR-, ABL+ CML Patients Nilotinib - Chronic Myeloid Leukemia | Phase 3 | Completed | Gruppo Italiano Malattie EMatologiche dell'Adulto | 109 | 2012-01-01 | 2018-08-06 |
| Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients Nilotinib - Chronic Myeloid Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 421 | 2011-04-01 | 2016-03-03 |
| Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients Nilotinib, Imatinib - Chronic Myeloid Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 267 | 2011-04-01 | 2016-04-08 |
| Allogeneic Stem Cell Transplantation for Children With CML Fludarabine, Thiotepa, Melphalan - Chronic Myeloid Leukemia | Phase 2 / Phase 3 | Completed | St. Anna Kinderkrebsforschung | 13 | 2009-04-30 | 2021-04-15 |
| A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Nilotinib - Chronic Myeloid Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 6 | 2009-01-01 | 2017-02-28 |
| Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib Nilotinib, Imatinib - Chronic Myeloid Leukemia | Phase 3 | Unknown | Seoul St. Mary's Hospital | 100 | 2009-01-01 | 2014-01-13 |
| Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML Bosutinib, imatinib - Chronic Myeloid Leukemia | Phase 3 | Completed | Pfizer | 502 | 2008-02-05 | 2019-01-08 |
| Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy StemEx® - Hematologic Malignancies, Acute Myeloid Leukemia | Phase 2 / Phase 3 | Completed | Gamida Cell -Teva Joint Venture Ltd. | 101 | 2007-10-01 | 2015-07-10 |
Showing 20 of 26. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (26) · Leukemia, Myeloid, Acute (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Lymphoma, Non-Hodgkin (3) · Myelodysplastic Syndromes (3) · Myeloproliferative Disorders (3) · Anemia, Refractory, with Excess of Blasts (2) · Primary Myelofibrosis (2) · Bone Marrow Diseases (1) · Bronchiolitis Obliterans Syndrome (1) · Gastrointestinal Stromal Tumors (1) · Graft vs Host Disease (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Hemoglobinuria, Paroxysmal (1)
Chronic Disease (26) · Disease Attributes (26) · Hemic and Lymphatic Diseases (26) · Pathologic Processes (26) · Pathological Conditions, Signs and Symptoms (26) · Bone Marrow Diseases (25) · Hematologic Diseases (25) · Leukemia (25) · Leukemia, Myeloid (25) · Neoplasms (25) · Neoplasms by Histologic Type (25) · Myeloproliferative Disorders (23) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6)
Imatinib Mesylate (11) · nilotinib (9) · Cyclophosphamide (2) · Dasatinib (2) · Mycophenolic Acid (2) · bosutinib (2) · fludarabine (2) · Antibodies (1) · Calcineurin Inhibitors (1) · Cyclosporine (1) · Cytarabine (1) · Drug Therapy (1) · Granulocyte Colony-Stimulating Factor (1) · Melphalan (1) · Methotrexate (1)
Novartis Pharmaceuticals (3) · Poitiers University Hospital (2) · Amneal Pharmaceuticals, LLC (1) · Ariad Pharmaceuticals (1) · Ascentage Pharma Group Inc. (1) · Bristol-Myers Squibb (1) · Central European Leukemia Study Group (1) · Dartmouth-Hitchcock Medical Center (1) · European LeukemiaNet (1) · Gamida Cell -Teva Joint Venture Ltd. (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Gruppo Italiano Trapianto di Midollo Osseo (1) · Hospices Civils de Lyon (1) · Hospital Israelita Albert Einstein (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1)
Italy (9) · France (7) · Germany (6) · United States (6) · Canada (5) · Czechia (4) · India (4) · Poland (4) · Russia (4) · South Korea (4) · Spain (4) · United Kingdom (4) · Australia (3) · Austria (3) · Belgium (3)
Agha Mounzer, MD (1) · Alberto Bosi, MD (1) · Alessandro Rambaldi, MD (1) · Andreas Hochhaus, Prof. MD (1) · Ashutosh Jani, MD (1) · Celia Grosskreutz, MD (1) · Christelle Ferra, MD (1) · Cristina Arbona, MD (1) · Dong-Wook Kim, MD, PhD (1) · Dr. Cristina Diaz de Heredia, MD (1) · Dr. Mi Kwon, MD (1) · Dr. Pere Barba, MD (1) · Elias Jabbour, M.D. (1)
PMID 19264678, PMID 19797518, PMID 20145273, PMID 21175313, PMID 21447834, PMID 21450900, PMID 22511495, PMID 22692507, PMID 22825216, PMID 22949154, PMID 23116602, PMID 24105694, PMID 24123600, PMID 24919837, PMID 24944159, PMID 25361995, PMID 25766724, PMID 26474455, PMID 27083332, PMID 27470600, PMID 27890936, PMID 28572163, PMID 28699641, PMID 29477778, PMID 29510895, PMID 29735299, PMID 34699069, PMID 35235189, PMID 37553873, PMID 42069411